Jeevan Dhruve S, Cooper Jared B, Braun Alex, Murali Raj, Jhanwar-Uniyal Meena
Department of Neurosurgery, New York Medical College, Valhalla, NY, U.S.A.
Department of Pathology, New York Medical College, Valhalla, NY, U.S.A.
Anticancer Res. 2016 Feb;36(2):523-32.
Brain metastases are the leading cause of morbidity and mortality among patients with disseminated cancer. The development of metastatic disease involves an orderly sequence of steps enabling tumor cells to migrate from the primary tumor and colonize at secondary locations. In order to achieve this complex metastatic potential, a cancer cell is believed to undergo a cellular reprogramming process involving the development of a degree of stemness, via a proposed process termed epithelial-to-mesenchymal transition (EMT). Upon reaching its secondary site, these reprogrammed cancer stem cells submit to a reversal process designated mesenchymal-to-epithelial transition (MET), enabling establishment of metastases. Here, we examined the expression of markers of EMT, MET, and stem cells in metastatic brain tumor samples.
Immunohistochemical analyses were performed to establish the markers of EMT and MET. Co-expression of these markers was determined by immunofluorescence analysis. Gene-expression analysis was conducted using tissues from brain metastases of primary adenocarcinoma of the lung compared to non-metastatic tissue. Cell proliferation was carried out using 3- (4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide S-phase entry analysis, by determining the 5-ethynyl-2'-deoxyuridine incorporation. Scratch wound and chemotactic migration assays were performed in an astrocytic setting.
Metastatic brain tumor samples displayed expression of epithelial markers (zinc finger protein SNAI1 and Twist-related protein-1), as well as the mesenchymal marker vimentin. The stem cell marker CD44 was also highly expressed. Moreover, co-expression of the epithelial marker E-cadherin with the mesenchymal marker vimentin was evident, suggesting a state of transition. Expression analysis of transcription factor genes in metastatic brain tumor samples demonstrated an alteration in genes associated with neurogenesis, differentiation, and reprogramming. Furthermore, tumor cells grown in astrocytic medium displayed increased cell proliferation and enhanced S-phase cell-cycle entry. Additionally, chemotactic signaling from the astrocytic environment promoted tumor cell migration. Primary tumor cells and astrocytes were also shown to grow amicably together, forming cell-to-cell interactions.
These findings suggest that cellular reprogramming via EMT/MET plays a critical step in the formation of brain metastases, where the cerebral milieu provides a microenvironment suitable for the development of metastatic disease.
脑转移瘤是播散性癌症患者发病和死亡的主要原因。转移性疾病的发展涉及一系列有序步骤,使肿瘤细胞能够从原发肿瘤迁移并在继发部位定植。为了实现这种复杂的转移潜能,癌细胞被认为会经历一个细胞重编程过程,通过一种称为上皮-间质转化(EMT)的过程,产生一定程度的干性。到达继发部位后,这些重编程的癌症干细胞会经历一个称为间质-上皮转化(MET)的逆转过程,从而形成转移瘤。在此,我们检测了转移性脑肿瘤样本中EMT、MET和干细胞标志物的表达。
进行免疫组织化学分析以确定EMT和MET的标志物。通过免疫荧光分析确定这些标志物的共表达。使用来自肺原发性腺癌脑转移瘤的组织与非转移组织进行基因表达分析。通过测定5-乙炔基-2'-脱氧尿苷掺入量,使用3-(4,5-二甲基噻唑-2-基)-2,5-二苯基四氮唑溴盐S期进入分析进行细胞增殖实验。在星形细胞环境中进行划痕伤口和趋化迁移实验。
转移性脑肿瘤样本显示上皮标志物(锌指蛋白SNAI1和Twist相关蛋白-1)以及间质标志物波形蛋白的表达。干细胞标志物CD44也高表达。此外,上皮标志物E-钙黏蛋白与间质标志物波形蛋白的共表达明显,提示处于转化状态。转移性脑肿瘤样本中转录因子基因的表达分析表明与神经发生、分化和重编程相关的基因发生了改变。此外,在星形细胞培养基中生长的肿瘤细胞显示细胞增殖增加和S期细胞周期进入增强。此外,来自星形细胞环境的趋化信号促进肿瘤细胞迁移。原发性肿瘤细胞和星形细胞也显示出友好地共同生长,形成细胞间相互作用。
这些发现表明,通过EMT/MET进行的细胞重编程在脑转移瘤的形成中起关键作用,其中脑环境提供了适合转移性疾病发展的微环境。